New York,  Scientists have developed an mRNA-based vaccine against all 20 known subtypes of influenza virus, which provided broad protection from otherwise lethal flu strains in initial tests.

This may serve as a general preventative measure against future flu pandemics in the near future, according to researchers from the Perelman School of Medicine at the University of Pennsylvania in the US.

The "multivalent" vaccine, described in a paper published in Science, uses the same messenger ribonucleic acid (mRNA) technology employed in the Pfizer and Moderna SARS-CoV-2 vaccines.

This mRNA technology that enabled those Covid-19 vaccines was pioneered at Penn.

Tests in animal models showed that the vaccine dramatically reduced signs of illness and protected from death, even when the animals were exposed to flu strains different from those used in making the vaccine.

"The idea here is to have a vaccine that will give people a baseline level of immune memory to diverse flu strains, so that there will be far less disease and death when the next flu pandemic occurs," said study senior author Scott Hensley, a professor of Microbiology at in the Perelman School of Medicine.

Influenza viruses periodically cause pandemics with enormous death tolls. The best known of these was the 1918-19 "Spanish flu" pandemic, which killed at least tens of millions of people worldwide.

Flu viruses can circulate in birds, pigs, and other animals, and pandemics can start when one of these strains jumps to humans and acquires mutations that adapt it better for spreading among humans.

Current flu vaccines are merely "seasonal" vaccines that protect against recently circulating strains, but would not be expected to protect against new, pandemic strains, said researchers.

"It would be comparable to first-generation SARS-CoV-2 mRNA vaccines, which were targeted to the original Wuhan strain of the coronavirus," Hensley said.

"Against later variants such as Omicron, these original vaccines did not fully block viral infections, but they continue to provide durable protection against severe disease and death," he added.

The experimental vaccine, when injected and taken up by the cells of recipients, starts producing copies of a key flu virus protein for all 20 influenza subtypes.

"For a conventional vaccine, immunising against all these subtypes would be a major challenge, but with mRNA technology it's relatively easy," Hensley said.

Hensley and his colleagues are currently designing human clinical trials.